SCHEMBL13435180

SCHEMBL13435180

COc1cc(CC2CCCN(C3C4CC5CC(C4)CC3C5)C2=O)cc(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.55
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KMT2A Q03164 1/20 0.36
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
ROCK2 O75116 1/20 0.34
ATM Q13315 1/20 0.34
TSHR P16473 1/20 0.34
KDM4E B2RXH2 1/20 0.34
RECQL P46063 1/20 0.34
HRH3 Q9Y5N1 2/20 0.33
SIGMAR1 Q99720 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3427613 0.93 HSD11B1 (0.64) HSD11B1ALDH1A1SMN1; SMN2ROCK2TSHR
SCHEMBL3428183 0.90 HSD11B1 (0.61) HSD11B1ALDH1A1SMN1; SMN2KMT2AROCK2
SCHEMBL13435178 0.84 HSD11B1 (0.58) HSD11B1ALDH1A1KMT2ATSHRKDM4E
SCHEMBL3421958 0.83 HSD11B1 (0.70) HSD11B1ALDH1A1SMN1; SMN2ROCK2HRH3
SCHEMBL13435176 0.77 HSD11B1 (0.59) HSD11B1ALDH1A1TSHRHRH3
SCHEMBL5043821 0.77 HSD11B1 (0.42) HSD11B1ALDH1A1SMN1; SMN2ROCK2TSHR
SCHEMBL13435181 0.77 HSD11B1 (0.68) HSD11B1ALDH1A1KMT2ATSHRKDM4E
SCHEMBL13435175 0.74 HSD11B1 (0.57) HSD11B1ALDH1A1SMN1; SMN2KMT2ASIGMAR1
SCHEMBL13435185 0.73 ALDH1A1 (0.35) HSD11B1ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL3427426 0.73 HSD11B1 (0.78) HSD11B1ALDH1A1SMN1; SMN2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687644-B2 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-03-30 US disclosed
US-7687644-B2 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-03-30 US disclosed
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 US disclosed
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors HSD11B1, HSD11B2, HSDL2 HSD11B1 1/4885ALDH1A1 99/4885SMN1; SMN2 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.